当前位置： SCI文献检索 > BIOLOGICAL PSYCHIATRY期刊下所有文献 > Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Abstract：

BACKGROUND:Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials. METHODS:Two randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in nonelderly (18-64 years) and elderly (≥65 years) patients with insomnia. Suvorexant doses of 40/30 mg (nonelderly/elderly) and 20/15 mg (nonelderly/elderly) were evaluated. The primary focus was 40/30 mg, with fewer patients randomized to 20/15 mg. There was an optional 3-month double-blind extension in trial 1. Each trial included a 1-week, randomized, double-blind run-out after double-blind treatment to assess withdrawal/rebound. Efficacy was assessed at week 1, month 1, and month 3 by patient-reported subjective total sleep time and time to sleep onset and in a subset of patients at night 1, month 1, and month 3 by polysomnography end points of wakefulness after persistent sleep onset and latency to onset of persistent sleep (LPS). One thousand twenty-one patients were randomized in trial 1 and 1019 patients in trial 2. RESULTS:Suvorexant 40/30 mg was superior to placebo on all subjective and polysomnography end points at night 1/week 1, month 1, and month 3 in both trials, except for LPS at month 3 in trial 2. Suvorexant 20/15 mg was superior to placebo on subjective total sleep time and wakefulness after persistent sleep onset at night 1/week 1, month 1, and month 3 in both trials and at most individual time points for subjective time to sleep onset and LPS in each trial. Both doses of suvorexant were generally well tolerated, with <5% of patients discontinuing due to adverse events over 3 months. The results did not suggest the emergence of marked rebound or withdrawal signs or symptoms when suvorexant was discontinued. CONCLUSIONS:Suvorexant improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated.

journal_name

Biol Psychiatry

journal_title

Biological psychiatry

authors

Herring WJ,Connor KM,Ivgy-May N,Snyder E,Liu K,Snavely DB,Krystal AD,Walsh JK,Benca RM,Rosenberg R,Sangal RB,Budd K,Hutzelmann J,Leibensperger H,Froman S,Lines C,Roth T,Michelson D

doi

10.1016/j.biopsych.2014.10.003

subject

Has Abstract

pub_date

2016-01-15 00:00:00

pages

136-48

issue

eissn

0006-3223

issn

1873-2402

pii

S0006-3223(14)00762-8

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.